Stock MDWD MEDIWOUND LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News MediWound Ltd.

Equities

MDWD

IL0011316309

Real-time Estimate Cboe BZX
Other stock markets
 03:24:57 2024-04-29 pm EDT 		5-day change 1st Jan Change
19.1 USD +4.74% Intraday chart for MediWound Ltd. +21.67% +88.54%
Mar. 21 MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 CI
Mar. 21 Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
GL
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
AQ
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026
CI
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M
MT
MediWound: Q4 Earnings Snapshot
AQ
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
GL
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study
MT
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
GL
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study
CI
MediWound to Participate in Two Upcoming Investor Conferences
GL
MediWound to Participate in Two Upcoming Investor Conferences
AQ
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA
MT
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
GL
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDWD Stock
  4. News MediWound Ltd.